How to Standardize Audit Risks and Legal Exposure Management Across Global Markets

The management of audit risks and legal exposure in the context of controlled substances compliance is a critical undertaking for pharmaceutical and biotech organizations operating across multiple regulatory landscapes, particularly in the US, UK, and EU. As regulatory authorities enforce stringent guidelines and compliance expectations, understanding the underlying regulations and fostering strategic documentation practices becomes paramount. This regulatory explainer provides an in-depth overview of the essential considerations in audit risk and legal exposure management concerning controlled substances compliance.

Context

As part of the broader category of regulatory affairs, the management of audit risks and legal exposure seeks to ensure compliance with applicable laws and regulations regarding controlled substances. These substances often possess the potential for abuse and, therefore, are subject to strict regulatory frameworks. Effective management in this area involves anticipating audits, preparing thoroughly for potential inspections, and understanding the consequences of non-compliance.

Various regulatory agencies including the FDA, EMA, and MHRA impose requirements on companies regarding controlled substances, compounding the complexity of compliance, documentation, and regulatory strategy. The ultimate goal for companies is to mitigate risk while ensuring approval and market access across jurisdictions.

Legal/Regulatory Basis

The foundation for audit risk management within the scope of controlled substances compliance is embedded in various regulations and guidelines:

• Title 21 of the Code of Federal Regulations (CFR): Specifically, 21 CFR parts 1300-1399 govern the United States’ controlled substances and set forth the standards for their handling, storage, and record-keeping.
• European Union Regulation No. 726/2004: This regulation establishes the framework for the centralized authorization of medicinal products, including those classified as controlled substances.
• UK Misuse of Drugs Act 1971: This legislation regulates the control of drugs and criminalizes the unauthorized possession, distribution, and manufacturing of controlled substances within the United Kingdom.
• International Council for Harmonisation (ICH) Guidelines: These guidelines, while primarily aimed at harmonizing drug development processes worldwide, also touch upon compliance requirements that affect controlled substances.

Documentation

Effective documentation practices form the backbone of successful audit risk and legal exposure management. Regulatory authorities scrutinize documentation closely, so understanding what to submit and how to present it is crucial.

Key Documentation Practices

• Establish a Controlled Substance Inventory: Maintain an accurate and up-to-date inventory reflecting all controlled substances handled, with accompanying records that detail the location, handling methods, and storage conditions.
• Standard Operating Procedures (SOPs): Develop comprehensive SOPs for handling, storage, and disposal of controlled substances and ensure they are adhered to by all employees.
• Training Records: Ensure all personnel handling controlled substances are trained appropriately. Document training sessions, materials used, and records of attendance.
• Compliance Audits: Conduct regular internal audits to assess compliance with controlled substance regulations and document findings and corrective actions.
• Incident Reports: Record any deviations from regulatory requirements, along with actions taken to address and rectify these issues.

Justification of Data

When filing for new products or variations related to controlled substances, organizations must justify their data adequately. This is particularly relevant when bridging data across different product formulations or geographies.

• Data Bridging Justification: Provide robust justification for any bridging data used in regulatory submissions, explaining how the data supports product safety and efficacy while complying with the regulatory standards of the region.
• Reference to Established Guidelines: Reference relevant ICH guidelines and local regulations to provide a framework for data interpretation that satisfies regulatory bodies.

Review/Approval Flow

The submission strategy for controlled substances must take into account the review and approval flow within regulatory agencies. A methodical approach to submissions helps mitigate delays and possible refusals.

Submission Strategies

• Determine Filing Type: Assess whether to file as a new application or as a variation based on the extent of changes made to the drug or its formulation. Considerations such as indications, dosage forms, and manufacturing processes are crucial in this decision.
• Pre-Submission Meetings: Engage in pre-submission meetings with regulatory authorities when possible. These meetings can clarify requirements and expectations, highlight potential obstacles and provide an early indication of agency questions.
• Time Management: Map out a submission timeline that accommodates for required internal reviews, edits, and adjustments, thus ensuring an inspection-ready submission.

Common Deficiencies

Understanding common deficiencies encountered in regulatory submissions or during inspections can aid organizations in proactively addressing potential issues:

• Inadequate Record Keeping: Missing or poorly maintained records may result in significant issues during audits. Ensure that all records are accurate, organized, and readily accessible.
• Lack of SOP Compliance: Failing to follow established SOPs can lead to procedural violations. Regular training and audits can help ensure adherence.
• Poor Training Documentation: Inadequate training records or lack of proof of training may lead to regulatory challenges. Retain clear documentation of all training sessions and employee participation.
• Failure to Report Deviations: Not reporting deviations or incidents promptly can exacerbate violations and penalties. Establish clear protocols for reporting and addressing deviations.

Interdepartmental Interactions

Regulatory Affairs cannot work in isolation; it interfaces with various departments, including Chemistry, Manufacturing, and Controls (CMC), Clinical Development, Pharmacovigilance (PV), Quality Assurance (QA), and Commercial teams.

Collaboration with CMC Team

The CMC team plays a critical role in ensuring that all materials used in the production of controlled substances are compliant with regulatory standards. Regular meetings to review product changes and updates are essential for regulatory filings.

Interaction with Clinical and PV Teams

The Regulatory Affairs team must collaborate with Clinical Development and PV teams to ensure that clinical trial data and safety information regarding controlled substances are accurately reported and aligned with regulatory expectations.

Quality Assurance Coordination

Maintaining compliance requires close collaboration with QA to regularly review practices and to ensure that documentation and processes meet regulatory standards.

Commercial Alignment

The Commercial team must be made aware of the compliance journey and any impact regulatory delays may have on market access and promotion strategies for controlled substances. Proactive customer engagement becomes critical in these situations.

Practical Tips for Inspection Readiness

To ensure inspection readiness, start by embedding a culture of compliance throughout the organization. Here are some practical tips:

• Conduct Mock Inspections: Simulating inspections can help identify potential issues in documentation and compliance processes, allowing for corrections before actual audits.
• Keep Audit Trails: Maintain thorough audit trails for all compliance activities and changes made in relation to controlled substances.
• Review and Update SOPs Regularly: Ensure that all SOPs remain relevant, accurate, and reflective of current practices and regulatory standards.
• Foster Open Communication: Promote communication between departments regarding compliance concerns, clarifying roles, responsibilities, and expectations.

Conclusion

In the increasingly regulated environment surrounding controlled substances, effective management of audit risks and legal exposure is paramount. By adhering to established regulations, maintaining clear documentation practices, and embracing an organizational culture of compliance, pharmaceutical and biotech companies can navigate the complexities of compliance and reduce their exposure to legal risks. Proactive engagement through interdepartmental collaboration and rigorous inspection preparation further solidifies the foundation needed for successful global operations.

For further details on regulations governing controlled substances, refer to the FDA’s guidance on controlled substances, or consult the European Medicines Agency’s resources.